SSStefan Sack

Stefan Sack

*This is an algorithmically generated author record based on publicly available information.

Stefan Sack has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Raimund Erbel

    From the Department of Cardiology (S.S., P.K., R.E.), West German Heart Center, Essen, Germany; the Department of Medicine (L.B.), Montreal Heart Institute, Montréal, Canada; the Department of Cardiology (L.P., V.L., P.L.), University Hospital of Liège, Liège, Belgium; the Department of Cardiology (R.H., P.S.), R-WTH University Hospital Aachen, Aachen, Germany; the Cardiovascular Center OLV Ziekenhuis (J.B., M.V.), Aalst, Belgium; Medical College of Wisconsin (D.M.), Milwaukee, Wis; and...

    3 shared publications
  • Florian Eyer

    Department of Clinical Toxicology and Poison Center Munich, Department of Internal Medicine II, TUM School of Medicine and Health, Technical University of Munich, TUM University Hospital Munich, Munich, Germany

    2 shared publications
  • Stefanie Geith

    Department of Clinical Toxicology and Poison Center Munich, Department of Internal Medicine II, TUM School of Medicine and Health, Technical University of Munich, TUM University Hospital Munich, Munich, Germany

    2 shared publications
  • Adinda Harle

    Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians-University, Leopoldstrasse 5, 80802, Munich, Germany

    1 shared publication
  • Amos Katz

    Department of Cardiology, Barzilai Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel

    1 shared publication
  • Cathrine Haller

    Department of Cardiology, Pneumology, and Intensive Care Medicine, Klinikum Schwabing, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität, Kölner Platz 1, 80804, Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    Lethal outcome of granulomatous acanthamoebic encephalitis in a man who was human immunodeficiency virus-positive: a case report

    by Stefanie Geith, Julia Walochnik, Franz Prantl, Stefan Sack, Florian Eyer

    Acanthamoeba species can cause disseminating infections in immunocompromised individuals. Here, we report a case of granulomatous acanthamoebic encephalitis with a lethal outcome in a 54-year-old German man who was human immunodeficiency virus-positive. The diagnosis was based on symptoms of progressive neurological deficits, including sensorimotor paralysis of his right leg and deteriorating alertness. Due to the rapid course and rather late diagnosis of the infection, effective treatment could not be applied and he died 12 days after hospital admission. To the best of our knowledge, this is the second case of granulomatous acanthamoebic encephalitis reported within Germany. Our case highlights the importance of early diagnosis of granulomatous acanthamoebic encephalitis to prevent fatal outcome.


  • Open Access

    Sustained low efficiency dialysis should not be interrupted for performing transpulmonary thermodilution measurements

    by Stefanie Geith, Lynne Stecher, Christian Rabe, Stefan Sack, Florian Eyer


  • Nichtkoronare Notfallinterventionen

    by Stefan Sack, Jun Nakata, Michael Steffen Dreher, Tobias Heer

    Minimal invasive catheter guided procedures are rapidly increasing. Most recently, new techniques for valve replacement (e. g. transcatheter aortic valve implantation, TAVI) and valve repair (e. g. Mitralclip and others) have been introduced. Other procedures are the closure of left atrial appendage, closure devices for shunts, procedures of the aorta and peripheral vessels. Emergent situations can occur in all interventions which require a safe and definite solution. On the other hand minimal invasive procedure can be used in an emergent situation which occurs primarily. These are balloon aortic valvuloplasty in cardiac decompensation, pericardial effluent and tamponade, acute aortic syndrome, acute lung embolism, peripheral vessel damage, percutaneous circulatory support devices, retrival of devices lost in the heart and circulatory system. We give here a survey on the available approaches for non-coronary emergencies.

  • Open Access

    Severe Plasmodium knowlesi infection with multi-organ failure imported to Germany from Thailand/Myanmar

    by Michael Seilmaier, Wulf Hartmann, Marcus Beissner, Thomas Fenzl, Cathrine Haller, Wolfgang Guggemos, Jan Hesse, Adinda Harle, Gisela Bretzel, Stefan Sack, et al.

    During the last two decades human infections with Plasmodium knowlesi are increasingly diagnosed in South East Asia and have also been reported in travellers. A severe case of imported P. knowlesi infection in a 73-year old German is presented, who had been travelling through Myanmar and Thailand for three weeks. Microscopy showed a parasitaemia of 3% and different parasite stages including band-forms resembling Plasmodium malariae. Due to the clinical picture of severe malaria and the microscopical aspect (combination of parasites resembling P. malariae and Plasmodium falciparum), P. knowlesi was suspected. The patient was treated with intravenous quinine; he was put on mechanical ventilation and catecholamines due to cardiorespiratory failure. Parasitaemia was cleared rapidly but renal function deteriorated resulting in intermittent haemodialysis. The patient was hospitalized for six weeks but he recovered completely without any physical sequelae. Plasmodium knowlesi mono-infection was confirmed by molecular methods later on. Plasmodium knowlesi infection has to be taken into account in feverish travellers returning from Thailand/Myanmar. Moreover this species can cause life-threatening or even lethal complications. Accordingly severe P. knowlesi infection should be treated like severe P. falciparum infections.


  • Open Access

    Potential Value of Automated Daily Screening of Cardiac Resynchronization Therapy Defibrillator Diagnostics for Prediction of Major Cardiovascular Events: Results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) Study

    by Stefan Sack, Christian Michael Wende, Herbert Nägele, Amos Katz, Wolfgang Rudolf Bauer, Craig Scott Barr, Klaus Malinowski, Harald Schwacke, Francisco Leyva, Jochen Proff, et al.

    Aim: To investigate whether diagnostic data from implanted cardiac resynchronization therapy defibrillators (CRT-Ds) retrieved automatically at 24 h intervals via a Home Monitoring function can enable dynamic prediction of cardiovascular hospitalization and death. Methods and results: Three hundred and seventy-seven heart failure patients received CRT-Ds with Home Monitoring option. Data on all deaths and hospitalizations due to cardiovascular reasons and Home Monitoring data were collected prospectively during 1-year follow-up to develop a predictive algorithm with a predefined specificity of 99.5%. Seven parameters were included in the algorithm: mean heart rate over 24 h, heart rate at rest, patient activity, frequency of ventricular extrasystoles, atrial–atrial intervals (heart rate variability), right ventricular pacing impedance, and painless shock impedance. The algorithm was developed using a 25-day monitoring window ending 3 days before hospitalization or death. While the retrospective sensitivities of the individual parameters ranged from 23.6 to 50.0%, the combination of all parameters was 65.4% sensitive in detecting cardiovascular hospitalizations and deaths with 99.5% specificity (corresponding to 1.83 false-positive detections per patient-year of follow-up). The estimated relative risk of an event was 7.15-fold higher after a positive predictor finding than after a negative predictor finding. Conclusion: We developed an automated algorithm for dynamic prediction of cardiovascular events in patients treated with CRT-D devices capable of daily transmission of their diagnostic data via Home Monitoring. This tool may increase patients’ quality of life and reduce morbidity, mortality, and health economic burden, it now warrants prospective studies. ClinicalTrials.gov NCT00376116.


  • Die kathetergestützte Implantation einer Aortenklappenprothese

    by Stefan Sack, Joachim Schofer

    Die kalzifizierte Aortenklappenstenose ist der häufigste erworbene Herzklappenfehler. Die Betroffenen sind ältere Menschen in der 8. und 9. Lebensdekade, die häufig zusätzlich Komorbiditäten wie linksventrikuläre Dysfunktion, eingeschränkte Nierenfunktion und pulmonale Hypertonie sowie weitere Begleiterkrankungen (Diabetes mellitus, Schlaganfall, chronisch- obstruktive Lungenerkrankung) aufweisen. Bei vielen dieser Patienten sind operative Morbidität und Letalität so hoch, dass der chirurgische Aortenklappenersatz nicht durchgeführt werden kann. Andererseits ist die Prognose der Aortenklappenstenose äußerst schlecht, sind die typischen Symptome wie Belastungsdyspnoe, Synkope und Angina pectoris erst einmal aufgetreten. Für diese Patientengruppe kommt derzeit die kathetergestützte Aortenklappenprothesenimplantation als eine alternative Behandlungsmethode in Betracht. Die Aortenklappenbioprothese besteht aus einem ballonexpandierbaren oder selbstexpandierenden Stent, in den eine Herzklappe aus Rinder- oder Schweineperikard fixiert ist. Die Implantation erfolgt über einen retrograden, transfemoralen Zugang, die ballonexpandierbare Klappenprothese kann auch transapikal eingebracht werden. Alternativ kann auch die Arteria subclavia als Zugangsweg gewählt werden. Immer häufiger wird die Intervention in Analgosedierung, d.h. am wachen Patienten durchgeführt, was nur über den femoralen Zugang möglich ist. Die weitere Verkleinerung der derzeitigen Klappenprothesen und neue Prothesentypen, die sich zurzeit im experimentellen Stadium oder bereits in der klinischen Prüfung befinden, tragen dieser Entwicklung Rechnung. The calcified aortic stenosis is the dominating valve disease. Patients affected are most common elderly people in the 8th or 9th decade of their life who often show associated comorbidities like reduced left ventricular function, impaired renal function, pulmonary hypertension, and further diseases (diabetes mellitus, stroke, chronic obstructive pulmonary disease). In many cases perioperative morbidity and mortality are too high for surgical valve replacement and patients are rejected. Nevertheless, prognosis of aortic stenosis is worse, if the typical symptoms like dyspnea on exertion, syncope, and angina occur. The transcatheter aortic valve implantation is an alternative treatment for this particular group of patients. The aortic valve bioprosthesis consists of a balloon-expandable stent or a self-expandable frame, in which a valve of bovine or porcine pericardium is incorporated. The implantation is performed by retrograde access via the femoral artery; the balloon-expandable prosthesis can also be implanted by transapical approach. Alternatively, the subclavian artery is chosen for access. More frequently, the implantation is performed in analgosedation with the patient awake that favors the transfemoral approach. A further reduction of the available prosthesis and new types of valves which are under current experimental tests and clinical evaluation contribute to this development.


  • Percutaneous Transvenous Mitral Annuloplasty

    by Stefan Sack, Philipp Kahlert, Luc Bilodeau, Luc A. PièrArd, Patrizio Lancellotti, Victor Legrand, Jozef Bartunek, Marc Vanderheyden, Rainer Hoffmann, Patrick Schauerte, et al.

    We assessed the safety and feasibility of permanent implantation of a novel coronary sinus mitral repair device (PTMA, Viacor Inc). Symptomatic (New York Heart Association class 2 or 3) patients with primarily functional mitral regurgitation (MR) were included. A diagnostic PTMA procedure was performed in the coronary sinus venous continuity. MR was assessed and the PTMA device adjusted to optimize efficacy. If MR reduction (> or =1 grade) was observed, placement of a PTMA implant was attempted. Implanted patients were evaluated with echocardiographic, quality of life, and exercise capacity metrics. Nineteen patients received a diagnostic PTMA study. Diagnostic PTMA was effective in 13 patients (MR grade 3.2+/-0.6 reduced to 2.0+/-1.0), and PTMA implants were placed in 9 patients. Four devices were removed uneventfully (7, 84, 197, and 216 days), 3 for annuloplasty surgery due to observed PTMA device migration and/or diminished efficacy. No procedure or device-related major adverse events with permanent sequela were observed in any of the diagnostic or implant patients. Sustained reductions of mitral annulus septal-lateral dimension from 3D echo reconstruction dimensions were observed (4.0+/-1.2 mm at 3 months). Percutaneous implantation of the PTMA device is feasible and safe. Acute results demonstrate a possibly meaningful reduction of MR in responding patients. Sustained favorable geometric modification of the mitral annulus has been observed, though reduction of MR has been limited. The PTMA method warrants continued evaluation and development.


  • Dekompensiertes Klappenvitium: das Revival der Ballonvalvuloplastie – perkutane Klappeninterventionen

    by Stefan Sack, Jochen Menne, Thomas Krüger, Michael Weber, Dieter Müller, Werner Zwehl


  • Percutaenous mitral valve: A non-stented coronary sinus device for the treatment of functional mitral regurgitation in heart failure patients

    by Stefan Sack, Philipp Kahlert, Raimund Erbel

    Functional mitral regurgitation in heart failure limits survival in a severity-graded fashion. Even mild mitral regurgitation doubles mortality risk. We report the use of a non-stented coronary sinus device to reduce mitral annulus dimension in order to re-establish mitral valve competence. The device (PTMA™, Viacor, Inc., Wilmington, MA, USA) consists of a multi-lumen PTFE (Teflon) PTMA catheter in which Nitinol (nickel-titanium alloy) treatment rods are advanced. For individual use up to three rods of different length and stiffness can be used. Therefore dimension reduction can be performed in an incremental fashion. Fluoroscopy and 3 D echocardiography are performed throughout the procedure to visiualize the positioning and confirm maximum treatment effect. The case describes the use and the effect of PTMA treatment. Safety and efficacy of the PTMA device will be investigated in the upcoming PTOLEMY 2 trial.